Ophthalmic Packaging Market to hit US$ 21.7 Bn, Growing at a CAGR of 16.4% During Forecast (2023-2033) - Persistence Market Research Study Analysis
January 11, 2023 09:30 ET
|
Persistence Market Research
New York, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The Ophthalmic Packaging Market revenues were estimated at US$ 4.2 Bn in 2021 and is anticipated to grow at a CAGR of 16.4% from 2022-2032, according to a...
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
January 10, 2023 16:05 ET
|
IRIDEX Corporation
MOUNTAIN VIEW, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal...
Digital Therapeutics Market Worth $22.16 Billion by 2030 - Exclusive Report by Meticulous Research®
January 10, 2023 09:00 ET
|
Meticulous Market Research Pvt. Ltd.
Redding, California, Jan. 10, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled ‘Digital Therapeutics Market by Component (Software, Device), Application (Diabetes,...
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
January 08, 2023 08:00 ET
|
Viridian Therapeutics, Inc
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated...
Global Ophthalmology PACS Market to Surpass US$ 319.17 Million by 2030, Says Coherent Market Insights (CMI)
January 06, 2023 09:15 ET
|
CMI
Burlingame, Jan. 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global ophthalmology PACS market is estimated to be valued at US$ 201.18 Million in 2022 and is expected to...
Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2
January 06, 2023 09:00 ET
|
Frontera Therapeutics
BEDFORD, Mass., and SHANGHAI, China, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy...
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
January 05, 2023 08:00 ET
|
Minovia Therapeutics
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight...
Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)
January 05, 2023 06:00 ET
|
Oculis
Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME) Oculis has completed enrollment for stage 1...
Ashvattha Therapeutics to Present at Biotech Showcase 2023
January 03, 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a...
Samsung Bioepis Announces Health Canada Approval of Citrate-Free High-Concentration of HUMIRA®¹ Biosimilar (adalimumab; SB5)
January 03, 2023 07:00 ET
|
Samsung Bioepis
With the approval, Samsung Bioepis has both low (40mg/0.8mL) and high (40 mg/0.4mL) concentration of adalimumab biosimilar approved in CanadaReaffirms its commitment to increasing accessibility by...